Clinical Trials Logo

Filter by:
NCT ID: NCT05567458 Recruiting - Beta-thalassemia Clinical Trials

A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.

Start date: October 17, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of luspatercept plus best supportive care (BSC) versus placebo plus BSC in participants who require regular red blood cell transfusions due to β-thalassemia.

NCT ID: NCT05567094 Completed - Clinical trials for Pancreaticoduodenectomy

The Effect of Perioperative DEXamethasone on Postoperative Complications After PANcreaticoduodenectomy

PANDEX
Start date: October 8, 2022
Phase: Phase 4
Study type: Interventional

The primary objective of this clinical trial is evaluate the effect of dexamethasone on postoperative complications after pancreaticoduodenectomy.

NCT ID: NCT05566600 Recruiting - Clinical trials for Chronic Heart Failure

Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure

Start date: October 9, 2022
Phase: Early Phase 1
Study type: Interventional

This study is designed to evaluate the safety and efficacy of allogeneic induced pluripotent cell derived cardiomyocytes (iPSC-CMs) in treating patients with worsening ischemic heart failure undergoing coronary artery bypass graft surgery. After screening, iPSC-CMs will be administrated intramyocardially in consented and eligible patients undergoing open-chest CABG surgery and the estimated population size for the study will be 32 patients.

NCT ID: NCT05566457 Recruiting - Breast Cancer Clinical Trials

HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BC

Start date: January 1, 2020
Phase: Phase 2
Study type: Interventional

The current treatments for albumin-bound paclitaxel (nab-PTX) -related peripheral neurotoxicity (PN) mainly included cryotherapy and compression therapy , oral B group vitamin , and duloxetine. However, treatment effectiveness of these three methods is limited. Huangqi Guizhi Wuwu decoction (HGWD) is an herbal formula recorded in "Synopsis of the Golden Chamber" for improving limb pain, tingling, and numbness, which is composed of five crude drugs (Astragali Radix, Cinnamomi Ramulus, Paeoniae Radix Alba, Zingiberis Rhizoma Recens, and Jujubae Fructus)(9). Recently, HGWD has been shown to be effective in the treatment of oxaliplatin- and diabetic-related PNs . But there are no prospective studies to explore the efficacy of HGWD in the treatment of nab-PTX-induced PN in patients with BC. Therefore, we conducted this prospective randomized controlled study to investigate the efficacy and safety of HGWD to prevent nab-PTX-induced PN in patients with BC. The primary aim of this study was to assess the prevention of nab-PTX-induced PN by soaking hands and/or feet with HGWD when compared to placebo.

NCT ID: NCT05566210 Recruiting - Clinical trials for Decreased Ovarian Reserve

Effects of Acupuncture on Ovarian Function and Pregnancy Outcomes in Women With Decreased Ovarian Reserve

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

The randomized, placebo-controlled multicenter trial is conducted in three centers in China. After screening and obtaining the signed informed consent, the participants are randomly divided into two groups: acupuncture group and sham acupuncture group.

NCT ID: NCT05566093 Recruiting - Clinical trials for Pancreatic Neuroendocrine Tumor

EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors

Start date: September 28, 2018
Phase: N/A
Study type: Interventional

The current study aims to access the feasibility, safety, and efficacy of EUS-FNI for nonfunctional pNETs

NCT ID: NCT05566054 Recruiting - Newly Diagnosed Clinical Trials

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

Start date: March 1, 2022
Phase: Phase 2
Study type: Interventional

This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy

NCT ID: NCT05566002 Recruiting - Clinical trials for Pulmonary Hypertension

Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension

AIPHY
Start date: June 1, 2022
Phase:
Study type: Observational

Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.

NCT ID: NCT05565807 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Start date: February 9, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase Ib/IIa, open-label, dose-escalation, and extension study to evaluate the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma.

NCT ID: NCT05565742 Active, not recruiting - Clinical trials for Lipoprotein Disorder

A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

Start date: October 20, 2022
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.